Logo
x

Search

Subscribe Now

Bladder Cancer

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US

  • March 8, 2021
AstraZeneca to Withdraw Imfinzi Indication in Advanced Bladder Cancer in the US

AstraZeneca to Withdraw Imfinzi Indication in Advanced Bladder Cancer in the US

  • February 22, 2021
Roche Presents Results of Tecentriq (atezolizumab) in P-III IMvigor010 Study for MIUC at ESMO 2020

Roche Presents Results of Tecentriq (atezolizumab) in P-III IMvigor010 Study for MIUC at ESMO 2020

  • December 11, 2020
AstraZenca's Imfinzi (durvalumab) Receives the US FDA's Approval for Less-Frequent Fixed-Dose Use

AstraZenca's Imfinzi (durvalumab) Receives the US FDA's Approval for Less-Frequent Fixed-Dose Use

  • November 20, 2020
AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Priority Review for Less Frequent Fixed-Dose Use in NSCLC and Bladder Cancer

AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Priority Review for Less Frequent Fixed-Dose Use in NSCLC and Bladder Can...

  • August 18, 2020
AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV Bladder Cancer

AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV Bladder Cancer

  • March 6, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.